Vertex Pharmaceuticals has signed a long-term supply agreement with Lonza to manufacture its gene therapy Casgevy. The US Food and Drug Administration approved the treatment for sickle cell disease in December 2023, making it the first CRISPR-based therapy to be approved in the US. Lonza says it will manufacture Casgevy at its facility in Geleen, Netherlands, and plans to expand to its plant in Portsmouth, New Hampshire.
Source link
